4//SEC Filing
Amble Erik 4
Accession 0000899243-18-030617
CIK 0001603756other
Filed
Dec 9, 7:00 PM ET
Accepted
Dec 10, 9:17 PM ET
Size
8.2 KB
Accession
0000899243-18-030617
Insider Transaction Report
Form 4
Amble Erik
Director10% Owner
Transactions
- Award
Common Stock
2018-12-06+2,500→ 2,500 total - Award
Stock Option (Right to Buy)
2018-12-06+5,000→ 5,000 totalExercise: $14.80Exp: 2028-12-06→ Common Stock (5,000 underlying)
Holdings
- 1,520,884(indirect: By NeoMed Innovation V, L.P.)
Common Stock
Footnotes (2)
- [F1]These shares are held of record by NeoMed Innovation V, L.P. ("NeoMed"). NeoMed Innovation V Limited is the general partner of NeoMed and has voting and dispositive power over the shares held by NeoMed. Erik Amble, Ph.D., who is a member of the Issuer's board of directors, is a director of NeoMed Innovation V Limited, and may be deemed to have voting and dispositive power over the shares held by NeoMed. Mr. Amble disclaims beneficial ownership of these securities and this report shall not be deemed an admission that Mr. Amble is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his respective pecuniary interest therein.
- [F2]The shares subject to the option will vest in full on April 30, 2019.
Documents
Issuer
Axonics Modulation Technologies, Inc.
CIK 0001603756
Entity typeother
Related Parties
1- filerCIK 0001756337
Filing Metadata
- Form type
- 4
- Filed
- Dec 9, 7:00 PM ET
- Accepted
- Dec 10, 9:17 PM ET
- Size
- 8.2 KB